Eurofins Issues EUR 650m New Euro Bond
July 18 2017 - 12:44PM
Business Wire
This document contains inside information
for the purpose of Regulation (EU) 596/2014 of the European
Parliament and of the Council of 16 April 2014 on market
abuse
Regulatory News:
Eurofins Scientific SE (Paris:ERF) (EUFI.PA, unrated), a global
leader in bioanalytical testing, announces that it has successfully
raised EUR 650m in its latest senior unsecured Euro bond public
issuance. The bonds have a 7-year maturity (due 25 July 2024) and
will bear an annual rate of 2.125%, the lowest coupon achieved by
Eurofins since its debut senior Euro bond issuance in November
2013. The issue was more than 4x times over-subscribed.
Eurofins intends to use the proceeds of the issuance for general
corporate purposes, including refinancing some of its existing debt
instruments, as well as to fund any further growth opportunity
in-line with the Group’s strategy and objectives. The new bond
further improves Eurofins’ liquidity position by lengthening its
debt maturity profile.
Comment from Dr. Gilles Martin, Eurofins CEO: “I am
pleased with the result of our latest public bond issuance. In
light of good market conditions and on the back of a strong M&A
activity thus far in 2017 as summarized in our press release of
yesterday, we have decided to lengthen our funding and optimize its
cost. In addition to refinancing a more expensive instrument (our
EUR 300m Euro bond bearing a 3.125% coupon that matures in November
2018), this bond strengthens our ability to respond swiftly to
compelling opportunities.”
BofA Merrill Lynch and BNP Paribas acted as global coordinators
and Crédit Agricole CIB, Natixis and UniCredit Bank acted as joint
bookrunners for the transaction.
The bonds will be listed from their issue date (25 July 2017) on
the regulated market of the Luxembourg stock exchange (ISIN
XS1651444140). The bonds are not registered under the US Securities
Act of 1933 as amended (the “Securities Act”), and may not be
offered or sold in the United States (as such term is defined in
Regulation S under the Securities Act) unless registered under the
Securities Act or pursuant to an exemption from such
registration.
For more information please visit
http://www.eurofins.com
Notes for the editor:
Eurofins – a global leader in bio-analysis
Eurofins Scientific SE through its subsidiaries (hereinafter
sometimes “Eurofins” or “the Group”) believes it is the world
leader in food, environment and pharmaceutical products testing and
that it is also one of the global independent market leaders in
certain testing and laboratory services for agroscience, genomics,
discovery pharmacology and for supporting clinical studies. In
addition, Eurofins is one of the key emerging players in specialty
clinical diagnostic testing in Europe and the USA. With over 30,000
staff in 375 laboratories across 41 countries, Eurofins offers a
portfolio of over 130,000 analytical methods for evaluating the
safety, identity, composition, authenticity, origin and purity of
biological substances and products, as well as for innovative
clinical diagnostic. The Group objective is to provide its
customers with high-quality services, accurate results on time and
expert advice by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by
expanding both its technology portfolio and its geographic reach.
Through R&D and acquisitions, the Group draws on the latest
developments in the field of biotechnology and analytical chemistry
to offer its clients unique analytical solutions and the most
comprehensive range of testing methods.
As one of the most innovative and quality oriented international
players in its industry, Eurofins is ideally positioned to support
its clients’ increasingly stringent quality and safety standards
and the expanding demands of regulatory authorities around the
world.
The shares of Eurofins Scientific SE are listed on the Euronext
Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg
ERF FP).
Important disclaimer:
This press release contains forward-looking statements and
estimates that involve risks and uncertainties. The forward-looking
statements and estimates contained herein represent the judgement
of Eurofins Scientific SE’s management as of the date of this
release. These forward-looking statements are not guarantees for
future performance, and the forward-looking events discussed in
this release may not occur. Eurofins Scientific SE disclaims any
intent or obligation to update any of these forward-looking
statements and estimates. All statements and estimates are made
based on the information available to the Company’s management as
of the date of publication, but no guarantee can be made as to
their validity.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170718006168/en/
Investor RelationsEurofins Scientific SEHugues Vaussy, Phone:
+32 2 766 1620Finance DirectorE-mail: ir@eurofins.com
Enerplus (NYSE:ERF)
Historical Stock Chart
From Feb 2024 to Mar 2024
Enerplus (NYSE:ERF)
Historical Stock Chart
From Mar 2023 to Mar 2024